vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Click either name above to swap in a different company.
TEVA PHARMACEUTICAL INDUSTRIES LTD is the larger business by last-quarter revenue ($4.7B vs $1.1B, roughly 4.1× Elanco Animal Health Inc). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs -24.1%, a 34.3% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 11.4%). TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $46.0M). Over the past eight quarters, TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue compounded faster (11.1% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
ELAN vs TEVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $4.7B |
| Net Profit | $-276.0M | $481.0M |
| Gross Margin | 51.5% | 56.4% |
| Operating Margin | -22.6% | 6.4% |
| Net Margin | -24.1% | 10.2% |
| Revenue YoY | 12.2% | 11.4% |
| Net Profit YoY | -3350.0% | 321.7% |
| EPS (diluted) | $-0.55 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $4.7B | ||
| Q3 25 | $1.1B | $4.5B | ||
| Q2 25 | $1.2B | $4.2B | ||
| Q1 25 | $1.2B | $3.9B | ||
| Q4 24 | $1.0B | $4.2B | ||
| Q3 24 | $1.0B | $4.3B | ||
| Q2 24 | $1.2B | $4.2B | ||
| Q1 24 | $1.2B | $3.8B |
| Q4 25 | $-276.0M | $481.0M | ||
| Q3 25 | $-34.0M | $433.0M | ||
| Q2 25 | $11.0M | $282.0M | ||
| Q1 25 | $67.0M | $214.0M | ||
| Q4 24 | $-8.0M | $-217.0M | ||
| Q3 24 | $364.0M | $-437.0M | ||
| Q2 24 | $-50.0M | $-846.0M | ||
| Q1 24 | $32.0M | $-139.0M |
| Q4 25 | 51.5% | 56.4% | ||
| Q3 25 | 53.4% | 51.4% | ||
| Q2 25 | 57.5% | 50.3% | ||
| Q1 25 | 57.3% | 48.2% | ||
| Q4 24 | 50.9% | 50.2% | ||
| Q3 24 | 52.2% | 49.6% | ||
| Q2 24 | 58.2% | 48.6% | ||
| Q1 24 | 57.3% | 46.4% |
| Q4 25 | -22.6% | 6.4% | ||
| Q3 25 | -4.4% | 19.7% | ||
| Q2 25 | 2.0% | 10.9% | ||
| Q1 25 | 5.0% | 13.3% | ||
| Q4 24 | -5.0% | -0.7% | ||
| Q3 24 | 54.3% | -1.2% | ||
| Q2 24 | -2.7% | -0.1% | ||
| Q1 24 | 1.0% | -5.7% |
| Q4 25 | -24.1% | 10.2% | ||
| Q3 25 | -3.0% | 9.7% | ||
| Q2 25 | 0.9% | 6.8% | ||
| Q1 25 | 5.6% | 5.5% | ||
| Q4 24 | -0.8% | -5.1% | ||
| Q3 24 | 35.3% | -10.1% | ||
| Q2 24 | -4.2% | -20.3% | ||
| Q1 24 | 2.7% | -3.6% |
| Q4 25 | $-0.55 | $0.42 | ||
| Q3 25 | $-0.07 | $0.37 | ||
| Q2 25 | $0.02 | $0.24 | ||
| Q1 25 | $0.13 | $0.18 | ||
| Q4 24 | $-0.01 | $-0.19 | ||
| Q3 24 | $0.73 | $-0.39 | ||
| Q2 24 | $-0.10 | $-0.75 | ||
| Q1 24 | $0.06 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $3.6B |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $7.9B |
| Total Assets | $13.4B | $40.7B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $3.6B | ||
| Q3 25 | $505.0M | $2.2B | ||
| Q2 25 | $539.0M | $2.2B | ||
| Q1 25 | $487.0M | $1.7B | ||
| Q4 24 | $468.0M | $3.3B | ||
| Q3 24 | $490.0M | $3.3B | ||
| Q2 24 | $416.0M | $2.3B | ||
| Q1 24 | $345.0M | $3.0B |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.8B | — |
| Q4 25 | $6.5B | $7.9B | ||
| Q3 25 | $6.7B | $7.3B | ||
| Q2 25 | $6.8B | $6.8B | ||
| Q1 25 | $6.4B | $6.3B | ||
| Q4 24 | $6.1B | $5.4B | ||
| Q3 24 | $6.5B | $6.1B | ||
| Q2 24 | $5.9B | $6.4B | ||
| Q1 24 | $6.1B | $7.3B |
| Q4 25 | $13.4B | $40.7B | ||
| Q3 25 | $13.6B | $39.9B | ||
| Q2 25 | $13.7B | $40.1B | ||
| Q1 25 | $12.9B | $38.4B | ||
| Q4 24 | $12.6B | $39.3B | ||
| Q3 24 | $13.3B | $41.8B | ||
| Q2 24 | $13.8B | $41.3B | ||
| Q1 24 | $14.0B | $42.8B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $1.2B |
| Free Cash FlowOCF − Capex | $46.0M | $1.0B |
| FCF MarginFCF / Revenue | 4.0% | 21.6% |
| Capex IntensityCapex / Revenue | 5.4% | 3.0% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $1.2B | ||
| Q3 25 | $219.0M | $369.0M | ||
| Q2 25 | $237.0M | $227.0M | ||
| Q1 25 | $-4.0M | $-105.0M | ||
| Q4 24 | $177.0M | $575.0M | ||
| Q3 24 | $162.0M | $693.0M | ||
| Q2 24 | $200.0M | $103.0M | ||
| Q1 24 | $2.0M | $-124.0M |
| Q4 25 | $46.0M | $1.0B | ||
| Q3 25 | $127.0M | $233.0M | ||
| Q2 25 | $180.0M | $131.0M | ||
| Q1 25 | $-69.0M | $-232.0M | ||
| Q4 24 | $130.0M | $446.0M | ||
| Q3 24 | $120.0M | $545.0M | ||
| Q2 24 | $166.0M | $6.0M | ||
| Q1 24 | $-22.0M | $-248.0M |
| Q4 25 | 4.0% | 21.6% | ||
| Q3 25 | 11.2% | 5.2% | ||
| Q2 25 | 14.5% | 3.1% | ||
| Q1 25 | -5.8% | -6.0% | ||
| Q4 24 | 12.7% | 10.5% | ||
| Q3 24 | 11.7% | 12.6% | ||
| Q2 24 | 14.0% | 0.1% | ||
| Q1 24 | -1.8% | -6.5% |
| Q4 25 | 5.4% | 3.0% | ||
| Q3 25 | 8.1% | 3.0% | ||
| Q2 25 | 4.6% | 2.3% | ||
| Q1 25 | 5.4% | 3.3% | ||
| Q4 24 | 4.6% | 3.1% | ||
| Q3 24 | 4.1% | 3.4% | ||
| Q2 24 | 2.9% | 2.3% | ||
| Q1 24 | 2.0% | 3.2% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | 21.55× | 0.80× | ||
| Q1 25 | -0.06× | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
